Literature DB >> 19464504

Expectant management in pregnancies with severe pre-eclampsia.

Bassam Haddad1, Baha M Sibai.   

Abstract

The main objective of expectant management in women with severe pre-eclampsia (PE) remote from term is to improve neonatal outcome. Maternal conditions, however, may worsen during expectant management. This highlights the importance of balancing the risks between maternal and perinatal outcomes. Traditionally, women with severe PE remote from term are delivered expeditiously, regardless of gestational age. We here have reported several retrospective, case-control, observational, prospective, or randomized trials in which expectant management in women with severe PE was feasible in well-selected patients without prejudicing maternal safety, and we have described our rationale and guidelines for this management.

Entities:  

Mesh:

Year:  2009        PMID: 19464504     DOI: 10.1053/j.semperi.2009.02.002

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  10 in total

1.  Maternal and fetal alternative complement pathway activation in early severe preeclampsia.

Authors:  M Camille Hoffman; Kristen K Rumer; Anita Kramer; Anne M Lynch; Virginia D Winn
Journal:  Am J Reprod Immunol       Date:  2013-10-16       Impact factor: 3.886

2.  Comparison of maternal and neonatal outcomes in women with HELLP syndrome and women with severe preeclampsia without HELLP syndrome.

Authors:  Abdulkadir Turgut; Oya Demirci; Elif Demirci; Mehmet Uludoğan
Journal:  J Prenat Med       Date:  2010-07

Review 3.  Pre-eclampsia: pathophysiology, diagnosis, and management.

Authors:  Jennifer Uzan; Marie Carbonnel; Olivier Piconne; Roland Asmar; Jean-Marc Ayoubi
Journal:  Vasc Health Risk Manag       Date:  2011-07-19

4.  Time from pre-eclampsia diagnosis to delivery affects future health prospects of children.

Authors:  Birgitte Hollegaard; Jacob A Lykke; Jacobus J Boomsma
Journal:  Evol Med Public Health       Date:  2017-02-08

5.  Maternal Perinatal Characteristics in Patients with Severe Preeclampsia: A Case-Control Nested Cohort Study.

Authors:  Irene Aracil Moreno; Patrocinio Rodríguez-Benitez; Maria Ruiz-Minaya; Mireia Bernal Claverol; Virginia Ortega Abad; Concepción Hernández Martin; Pilar Pintado Recarte; Fátima Yllana; Cristina Oliver-Barrecheguren; Melchor Álvarez-Mon; Miguel A Ortega; Juan A De Leon-Luis
Journal:  Int J Environ Res Public Health       Date:  2021-11-10       Impact factor: 3.390

6.  A matched pair cluster randomized implementation trail to measure the effectiveness of an intervention package aiming to decrease perinatal mortality and increase institution-based obstetric care among indigenous women in Guatemala: study protocol.

Authors:  Edgar Kestler; Dilys Walker; Anabelle Bonvecchio; Sandra Sáenz de Tejada; Allan Donner
Journal:  BMC Pregnancy Childbirth       Date:  2013-03-21       Impact factor: 3.007

7.  Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.

Authors:  Jeanne Sibiude; Jean Guibourdenche; Marie-Danielle Dionne; Camille Le Ray; Olivia Anselem; Raphaël Serreau; François Goffinet; Vassilis Tsatsaris
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

8.  Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?

Authors:  A S Critchfield; J K Paulus; R Farez; A C Urato
Journal:  J Perinatol       Date:  2013-05-23       Impact factor: 2.521

9.  Maternal near miss and death among women with severe hypertensive disorders: a Brazilian multicenter surveillance study.

Authors:  Elvira Zanette; Mary Angela Parpinelli; Fernanda Garanhani Surita; Maria Laura Costa; Samira Maerrawi Haddad; Maria Helena Sousa; Joao Luiz Pinto E Silva; Joao Paulo Souza; Jose Guilherme Cecatti
Journal:  Reprod Health       Date:  2014-01-16       Impact factor: 3.223

10.  Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio.

Authors:  Cecilia Villalaín; Ignacio Herraiz; Leonor Valle; Manel Mendoza; Juan Luis Delgado; María Vázquez-Fernández; Juan Martínez-Uriarte; Íñigo Melchor; Sara Caamiña; Antoni Fernández-Oliva; Olga Patricia Villar; Alberto Galindo
Journal:  J Am Heart Assoc       Date:  2020-04-04       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.